Is BMRN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Voxzogo growth engine, with revenue (ttm) at ~$3.41B. The bear case rests on revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Analysts covering it are spread from $60.00 to $124.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $60.00, +9.7% from the $54.68 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Voxzogo growth engine. Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. The most optimistic analyst target on BMRN is $124.00, +126.8% from the $54.68 price. That figure is only reachable if this thesis works close to its best case.

Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is building, including Ascendis Pharma's TransCon CNP and BridgeBio's achondroplasia drug, which received FDA priority review in October 2026, plus multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk and roughly $4.2 billion of debt, the Alesta deal brings a $1.50 hit to Q3 adjusted EPS, and the Roctavian withdrawal shows that expensive programs can fail commercially. GAAP earnings are thin (a trailing P/E near 149), so the low forward multiple only holds if guided growth and accretion materialize. Analysts have been trimming targets, for example UBS cutting to $88 from $114 in October while keeping a Buy rating. The most pessimistic published target is $60.00, +9.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Voxzogo growth engine) stalling in the reported numbers rather than in the narrative, the risk above (revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

BioMarin develops and commercializes therapies for rare genetic diseases. Its portfolio includes enzyme replacement therapies for lysosomal and metabolic disorders, Voxzogo for children with achondroplasia, and, following the 2026 Amicus acquisition, Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease. In September 2026 it added an early-stage hypophosphatasia program through the Alesta acquisition.

BMRN trades on the Nasdaq, so you can buy shares through any brokerage account, either as a standalone position or as part of a healthcare or rare-disease themed basket. Some investors also gain exposure indirectly through biotech and healthcare ETFs that hold the stock.

That depends on your goals, time horizon and risk tolerance, and Walnut is not an investment adviser. The descriptive picture is a profitable rare-disease specialist with accelerating revenue, concentrated product risk and new competition in achondroplasia, trading near 8 times forward earnings in October 2026, so it is worth weighing the growth drivers against the risks yourself or with a licensed adviser.